Committee for Melbourne – Welcome to our new CEO, Mark Melvin!
Posted: 2 June 2022. I would firstly like to say thank you to our members, stakeholders and secretariat for such a warm welcome. It is in an honour and a privilege to lead the Committee for Melbourne into…
Amplia Therapeutics (ASX:ATX) shows efficacy in model of lung fibrosis
Date posted: 2 June 2022 Amplia has released new data showing that in a head-to-head preclinical comparison, using a mouse model of idiopathic pulmonary fibrosis (IPF), AMP945 showed comparable efficacy to the current standard of care. The current…
Avatar Brokers Celebrates 20 Years
Posted: 30 May 2022 Avatar Brokers are proud to announce a significant milestone in the history of our company, with this month marking our 20th anniversary. Founded on May 29, 2002, Avatar Brokers began its operations after establishing…
Deadly partnership to bolster First Nations representation in medical research
Posted: 27 May 2022 WEHI has partnered with leading Indigenous not-for-profit, DeadlyScience, to foster the next generation of Aboriginal and Torres Strait Islander scientists, in the first partnership of its kind. At a glance WEHI partners with DeadlyScience to pave the…
Burnet Institute partners with Moderna to develop novel mRNA vaccines
Posted: 26 May 2022 Media Release: 18 May 2022 Burnet Institute is to partner with world-leading mRNA vaccine manufacturer Moderna, through their cutting-edge mRNA Access program, to develop novel mRNA vaccines for a range of emerging and neglected infectious…
Regulation of Cosmetics in Australia
Posted: 24 May 2022 Stephens Lawyers & Consultants Introduction The importation, manufacture, advertising and supply of cosmetics in Australia is highly regulated and complex. Before a cosmetic product or range can be launched in the Australian market –…
AI created Inventions or Works – Are they protected by Australian IP laws?
Posted: 24 May 2022 Katarina Klaric, Principal, Stephens Lawyers & Consultants Artificial intelligence (AI) and automated decision-making technology is being deployed by government and business to automate or improve operational capabilities. AI technology or systems also are increasingly…
VivaZome to collaborate with UQ Traumatic Brain Injury experts to develop exosome-based therapies
Posted: 20 May 2022 19th May 2022; Melbourne, Australia: VivaZome Therapeutics Pty Ltd (VivaZome) today announced that it has entered into a Memorandum of Understanding (MoU) with The University of Queensland (UQ) focussing on improved therapies for Traumatic…
ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
Posted: 19 May 2022 Sydney, Australia, 11th May 2022 – ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join…
$180m redevelopment of St Vincent’s Private Hospital Fitzroy set to begin
Posted: 19 May 2022 Construction set to begin on $180 million St Vincent’s Private Hospital Fitzroy redevelopment St Vincent’s Health Australia will mark the start of construction of its state-of-the-art, $180m Fitzroy private hospital redevelopment with a sod-turning…
Bionics Institute Excellence in Medical Device Innovation Award – nominations close 13 May
Posted: 6 May 2022 Nominations close: 13 May 2022 Nominations for the Bionics Institute 2022 Award for Excellence in Medical Device Innovation close on Friday 13 May. This accolade recognises an Australian who, through innovation, has made a…
Tessara Therapeutics reinforces Advisory Board with the appointment of global industry leaders in 3D tissue models for drug discovery and cell therapies
Posted: 3 May 2022 Tessara Therapeutics, an Australian biotechnology company developing synthetic human brain micro-tissues as drug screening and neuro-regenerative medicine platforms, continues to ready itself for commercial entry with a series of high-profile Advisory Board appointments. Tessara…
